Market Segmentation
By Types of Migraine
On the basis of types of migraine, the market is segmented into episodic, chronic, migraine with aura and others
In 2020, episodic segment is expected to dominate the market as the volume of episodic migraine attack increases as compared to other types of migraine
By Treatment
On the basis of treatment, the market is segmented into acute/abortive treatment, preventive/prophylactic treatment, non-pharmacological therapies and devices
In 2020, acute/abortive treatment is expected to dominate the market as several types of medications are available to treat acute migraine including the safe and popular drugs
By Route of Administration
On the basis of route of administration, the market is segmented into oral, parenteral, nasal sprays and others
In 2020, oral segment is expected to dominate the market due to the presence of large number of oral formulations for migraine treatment
By Product Type
On the basis of product type, the market is segmented into prescription and over the counter
In 2020, prescription segment is expected to dominate the market as only few medications that are patients revert to in case of emergency are available over the counter
By End-User
On the basis of end user, the market is segmented into hospitals, clinics, homecare and others
In 2020, hospital segment is expected to dominate the market as most of the patients have to visit hospitals due to severity of migraine attacks
By Distribution Channel
On the basis of distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, online pharmacies and others
In 2020, hospital pharmacies segment is expected to dominate the market as majority of prescription drugs are available over the hospital pharmacies and also patients feel convenient to purchase drugs from hospital pharmacy
Major Players
The major players covered in the report are Amgen Inc., Eli Lilly and Company, GlaxoSmithKline plc., Novartis AG, Bayer AG, Allergan, Abbott, AOBiome, AstraZeneca, Bausch Health Companies Inc, Boehringer Ingelheim International GmbH, Catalent, Inc, Dr. Reddy’s Laboratories Ltd., Lundbeck, Merck Sharp & Dohme Corp (A Subsidiary of Merck & Co., Inc.), Pfizer Inc., Otsuka Pharmaceutical Co., Ltd (A Subsidiary of Otsuka Holdings Co., Ltd.), Sun Pharmaceutical Industries Ltd among others